AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06669429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single ascending dose
Study NCT06219902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Oral administration of multiple doses of elinzanetant.
Study NCT03602898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO
Study NCT03602898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT06669429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a multiple ascending dose
Study NCT06669429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RS-C1001
Description: Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast
Study NCT06669429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
Study NCT03602898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT03602898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo peripheral blood stem cell transplantation
Study NCT03602898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03602898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03602898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT03602898 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT06669429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
Study NCT05695235 — intervention group
Intervention type: DEVICE
Intervention: CGM
Description: Wearable continuous glucose monitoring systems (CGMS) provide a minimally invasive means of passively tracking ambulant interstitial fluid glucose levels in real time.
Study NCT05695235 — intervention group
Intervention type: DEVICE
Intervention: Oura ring
Description: Wearable sleep tracking device
Study NCT06219902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to elinzanetant
Description: Oral administration
Study NCT05695235 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive tasks and questionnaires
Description: Participants will be prompted daily to fill out a short set of wellbeing questions and perform a short alertness test on their mobile phones and laptop.
Study NCT06219902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Oral administration
Study NCT06219902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to zopiclone
Description: Oral administration
Study NCT05194631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadriceps microbiopsy using a Tru-Cut biopsy needle
Description: During surgery for a benign or malignant tumor of the liver a quadriceps microbiopsy will be performed. A 1 cm incision of the skin and fat planes will be made using a scalpel until contact with the quadriceps aponeurosis. The biopsy needle will be inserted superficially into the muscular part allowing, through a suction system, a micro biopsy of the quadriceps of approximately 25 mg.
Study NCT05904873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Third Molar Surgery
Description: All surgical procedures were carried out by a single dental(maxillofacial) surgeon different from the clinician performing the cold testing. A total of 4 cc of local anesthetic solution containing 40 mg/ml articaine and 0.005 mg/ml epinephrine was applied to the inferior alveolar and buccal nerve blocks before the surgical procedure. In all cases, the mucoperiosteal flap was raised and bone was removed from the buccal and distal parts of the impacted tooth with burs, while protecting the papilla between the first and second molars during flap design. Before extraction, if necessary, the third molar was divided and tooth extraction was performed with elevators. The flap was brought to its original position and closed with silk suture material.
Study NCT04766892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mavacamten
Description: mavacamten capsules
Study NCT05129501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Tiwahe Wicagwicayapi seven-session program is for children ages 10 to 14 who are Native American and/or living in poverty and their caregivers. The program begins with a traditional Lakota meal followed by family time and break-out time for caregivers only and children only. The program includes skill-building activities as well as the integration of Lakota language, history, and culture. The program is facilitated by diverse individuals, predominantly Native Americans in Rapid City and surrounding tribal communities.
Study NCT06669429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
Study NCT06669793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biolimus-coated balloon
Description: 238 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of Biolimus-coated balloon.
Study NCT06669793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-coated balloon
Description: 237 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of paclitaxel-coated balloon.
Study NCT06669988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR
Description: VR - Immersive instruction using virtual reality.
Study NCT06669988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video
Description: Video - Educational content presented through video.
Study NCT06669988 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: written materials
Description: Written Materials - Instruction using text and images.
Study NCT06670807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Arm
Description: Fifty of the participants will consume 1 capsule/day of the dietary supplement AB-MIND+CECT7481 for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the intervention period.
Study NCT06670807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fifty of the participants will consume 1 capsule/day of the PLACEBO for 16 weeks. The capsule should be taken just before breakfast. The researchers will instruct the volunteers to maintain their usual lifestyle (diet, physical activity, sleep habits) throughout the entire intervention period.
Study NCT05316103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy targeted optical biopsy
Description: After intravenous injection of fluorescein sodium, pCLE-based targeted optical biopsy will be performed.
Study NCT06381726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resting State Functional Magnetic Resonance Imaging (rs-fMRI)
Description: rs-fMRI + neurological and neuropsychological evaluation at preoperative timepoint and 1-2 months postop, 3-4 months postop, 6-8 months postop, 12 months postop
Study NCT06381726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up-front Motor Rehabilitation
Description: personalized motor rehabilitation for 6 months + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months postop
Study NCT06381726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up-front Chemotherapy
Description: Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post
Study NCT06450600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Therapeutic Education Program
Description: The MS Self-Management Education Workshop is designed as an integral part of our therapeutic education program targeting individuals diagnosed with multiple sclerosis (MS). This intervention focuses on empowering participants with knowledge and skills necessary for effective self-management of their condition. The workshop includes interactive sessions that cover a range of topics critical for MS patients, such as:~Understanding the nature and progression of MS, highlighting the importance of early symptom recognition and management strategies.~Techniques for managing common MS symptoms, including fatigue, mobility issues, and cognitive challenges, with practical advice on daily living adaptations.~Guidance on medication management, including the use of disease-modifying therapies and managing side effects.~Strategies for emotional well-being, including coping mechanisms for dealing with the psychological impact of MS, stress management, and fostering resilience.
Study NCT06670742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: running
Description: Running 10 kilometers on a treadmill
Study NCT06367504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DBMF
Description: Once a day daily 30 minutes before lunch
Study NCT06367504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day daily 30 minutes before lunch
Study NCT04601883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: The intervention tablets are commercially available Colchicine Tiofarma
Study NCT04601883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo tablets. Placebo is identical to the active intervention.
Study NCT06240403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.125 MG
Description: One capsule containing digoxin per day for three months
Study NCT06240403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Digoxin 0.125 MG
Description: One capsule containing digoxin per day for three months
Study NCT06291298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGMUSE-AUT
Description: The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
Study NCT06266611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fsCBD Cannabidiol
Description: Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
Study NCT06266611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
Study NCT06266611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsCBD Cannabidiol
Description: Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
Study NCT06168994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Amiodarone vs eplerenone in AF
Study NCT06168994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Amiodarone vs eplerenone in AF
Study NCT06291935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG901
Description: Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)
Study NCT06025526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aktivplan
Description: The aktivplan digital intervention consists of a digital planning calendar for regular heart-healthy physical activity Towards the end of rehabilitation phase II, health professionals introduce aktivplan and plan a personalised physical activity plan together with their patients using shared decision-making. The physical activity plan is devised for the time after discharge from cardiac rehabilitation.~In the aktivplan smatphone app, the patient can view their personalised physical activity plan, check off completed activities, enter additional unplanned activities, and open short videos with exercise instructions.~Additional functions of aktivplan include patient-centered goal-setting, automated messages to the patient (motivational messages and reminders), and the possibility for health professionals to monitor all their patients' adherence to the physical activity plan and to contact individual patients directly via the app.
Study NCT06025526 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care (standard of care) according to international and national cardiac rehabilitation guidelines.
Study NCT06703255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX301+/Temozolomide
Description: Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional 3 + 3 rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each.
Study NCT06759649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM503
Description: Intravenous Infusion
Study NCT06759649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Intravenous infusion
Study NCT06773403 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Upadacitinib
Description: All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.
Study NCT06774300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS
Description: The intervention is the BASICS protocol outlined in the BASICS manual. It includes an online self-administered assessment and then delivery of a feedback session either in-person or over Zoom.
Study NCT06774300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online alcohol programming
Description: This is a control intervention that is used as the first-line sanction for students at the two universities. It is an online program, informed by BASICS content, but contains no facilitator and is self-directed.
Study NCT06777485 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure/Surgery treatment
Description: Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
Study NCT06777485 — intervention group
Intervention type: DRUG
Intervention: Anti-Tumor Drugs
Description: Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Study NCT06776185 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Surgery
Description: Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement. Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
Study NCT06776653 — intervention group
Intervention type: OTHER
Intervention: Tovertafel Pixie
Description: The Tovertafel Pixie® projector has a distracting effect, which can help divert the patient's attention while waiting for or undergoing treatment.
Study NCT06509906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9466
Description: M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.
Study NCT06509906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.
Study NCT06509906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid will be administered intravenously q2w as per standard of care.
Study NCT06509906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: Fluorouracil will be administered intravenously as per standard of care.
Study NCT06509906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.
Study NCT06775912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-05 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
Study NCT06775379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azetukalner
Description: Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
Study NCT06775379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Study NCT05642611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, plasma, and serum
Study NCT05642611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood, plasma, and serum
Study NCT05642611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryocompression Therapy
Description: Undergo cryocompression
Study NCT05642611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Therapy
Description: Undergo continuous compression
Study NCT05642611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Compression Therapy
Description: Undergo low cyclic compression
Study NCT05642611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05642611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05642611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05642611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06019130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases
Study NCT03762395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-10
Description: 6 weeks of treatment with 150 mg/day of orally administered CXA-10
Study NCT03762395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
Study NCT06081660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACP-I Plan
Description: ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
Study NCT06081660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP-I Plan
Description: ACP-I Plan consisting of education, counseling, decisional support, and patient navigation
Study NCT06267326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridment
Description: resection of dead bone
Study NCT06267326 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: debridment
Description: resection of dead bone
Study NCT04966351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding
Description: Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
Study NCT04966351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Misalignment
Description: Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.